The Legacy Effect in Treating Hypercholesterolemia

Kostis, John B.; Shetty, Mrinali; Chowdhury, Yuvraj S.; Kostis, William J.

doi:10.1177/1074248420907256

Cited by 6 publications

(2 citation statements)

References 41 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early and intensive lowering of hyperglycaemia has been associated with reduced complication development years after cessation of intensive glucose lowering (58). This "metabolic memory" has been similarly reported for early lowering of LDL-cholesterol levels (LDL-C) with statin treatment (187), and emphasises the importance of early lowering of glycaemic and LDLcholesterol levels. In view of poorer glycaemic and lipid profiles at diagnosis in YOD, it is important to explore whether subsequent glycaemic and lipid levels remain poor.…”

Section: 1supporting

confidence: 58%

Providing care for young adults with type 2 diabetes in primary care settings in Singapore: a multi-faceted study

Wong¹

View full text Add to dashboard Cite

Section: 1supporting

confidence: 58%

Providing care for young adults with type 2 diabetes in primary care settings in Singapore: a multi-faceted study

Wong¹

View full text Add to dashboard Cite

“…Some patients need combination therapy with other drugs to control blood pressure better. ARBs can be combined with thiazide diuretics, amlodipine or calcium channel blockers (CCB), neprilysin inhibitors, or beta‐blockers [53,54] . Combination therapy has more benefits but also more costs and risks [55]…”

Section: Arbsmentioning

confidence: 99%

Nanotechnology‐Based Strategies for Extended‐Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review

Haji Ali,

Shirvaliloo,

Fathi‐Karkan

et al. 2023

Chemistry & Biodiversity

View full text Add to dashboard Cite

There has been a significant shift in the perception of hypertension as an important contributor to the global disease burden. Approximately 6% and 8% of pregnancies are affected by hypertension, which can adversely affect the mother and the fetus. Furthermore, a hypertensive individual is at increased risk of developing kidney disease, arterial hardening, eye damage, and strokes. Using angiotensin receptor blockers (ARBs) is widespread in treating hypertension, heart failure, coronary artery disease, and diabetic nephropathy. Despite this, some ARBs have limited use due to their poor oral bioavailability and water solubility. To tackle this, a variety of nanoparticle (NP)‐based systems, such as polymeric NPs (i.e., dendrimers), polymeric micelles, polymer‐drug conjugates, lipid NPs, nanoemulsions, self‐emulsifying drug delivery systems (SEDDS), solid lipid NPs (SLNs), nanostructured lipid carriers (NLCs), carbon‐based nanocarriers, inorganic NPs, and nanocrystals, have been recently developed for efficient delivery of losartan, Valsartan (Val), Olmesartan (OLM), Telmisartan (TEL), Candesartan, Eprosartan, Irbesartan, and Azilsartan to target cells. This review article provides a literature‐based comparison of the various classes of ARBs, their mechanisms of action, and an overview of the nanoformulations developed for ARB delivery and successfully applied to managing hypertension, diabetic complications, and other conditions.

show abstract

Molecular mechanism study and potential active ingredients prediction of Danhe granules in the treatment of hypercholesterolemia via TICE

Shibo,

Tong,

Sili

et al. 2024

Peptide Science

View full text Add to dashboard Cite

This study aims to explore the molecular mechanism and potential active ingredients of Danhe granules in improving the blood lipid level of hypercholesterolemia by intestinal TICE (transintestinal cholesterol excretion) through in vivo experimental research, network pharmacology methods, and molecular docking. The diet‐induced hypercholesterolemia rat model evaluated the effects of Danhe granules on fecal cholesterol levels and intestinal TICE‐related protein expression in rats. Based on the experimental results, the network pharmacology method was used to predict the potential active ingredients, and the binding strength between the potential active ingredients and key targets was further confirmed by molecular docking. Danhe granules increased LDLR, ABCG5, ABCB1, and LXRα which can promote the uptake of cholesterol by intestinal cells and the excretion of cholesterol into the intestine, and then reduce the levels of serum LDL‐C and TC and increase the level of fecal TC, so as to achieve the effect of treating hypercholesterolemia. The results of network pharmacology and molecular docking showed that 19 active ingredients had good binding activity with the targets. These may be the active ingredients of Danhe granules for the treatment of hypercholesterolemia. This study revealed the molecular mechanism of Danhe granules in the treatment of hypercholesterolemia via TICE, and preliminarily clarified the potential effective ingredients. It provides new ideas for the treatment of hypercholesterolemia and the development of new drugs.

show abstract

The Legacy Effect in Treating Hypercholesterolemia

Cited by 6 publications

References 41 publications

Providing care for young adults with type 2 diabetes in primary care settings in Singapore: a multi-faceted study

Providing care for young adults with type 2 diabetes in primary care settings in Singapore: a multi-faceted study

Nanotechnology‐Based Strategies for Extended‐Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review

Molecular mechanism study and potential active ingredients prediction of Danhe granules in the treatment of hypercholesterolemia via TICE

Contact Info

Product

Resources

About